Acceleron Pharma (XLRN) Stock Price, News & Analysis

Acceleron Pharma Inc. (NASDAQ:XLRN) posted its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts' consensus estimates of ($0.98) by $0.18. The biopharmaceutical company had revenue of $34.20 million for the quarter, compared to the consensus estimate of $35.39 million. Acceleron Pharma had a negative trailing twelve-month return on equity of 32.11% and a negative net margin of 226.01%. The company's revenue for the quarter was up 51.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.66) EPS.

11 employees have rated Acceleron Pharma Chief Executive Officer Habib Dable on Glassdoor.com. Habib Dable has an approval rating of 100% among the company's employees. This puts Habib Dable in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Advanced Micro Devices (AMD), Gilead Sciences (GILD), NVIDIA (NVDA), Incyte (INCY), Intel (INTC), Pfizer (PFE), Corcept Therapeutics (CORT), Cisco Systems (CSCO) and Regeneron Pharmaceuticals (REGN).